{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:53:35Z","timestamp":1778158415478,"version":"3.51.4"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.11777","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T15:31:48Z","timestamp":1598283108000},"page":"e2011777","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer"],"prefix":"10.1001","volume":"3","author":[{"given":"Seema","family":"Gulia","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadhana","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Badwe","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"issue":"16","key":"zoi200454r1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi200454r2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi200454r3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer.","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi200454r4","article-title":"Trastuzumab containing regimens for early breast cancer.","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"zoi200454r5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"9897","key":"zoi200454r6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"zoi200454r7","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.breast.2013.07.029","article-title":"Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.","volume":"22","author":"Pinto","year":"2013","journal-title":"Breast"},{"issue":"5","key":"zoi200454r8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy.","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"12","key":"zoi200454r9","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/annonc\/mds127","article-title":"Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis.","volume":"23","author":"Tarantini","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi200454r10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","article-title":"Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis.","volume":"21","author":"Long","year":"2016","journal-title":"Oncologist"},{"issue":"12","key":"zoi200454r11","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/bjc.2015.405","article-title":"Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).","volume":"113","author":"Schneider","year":"2015","journal-title":"Br J Cancer"},{"issue":"12","key":"zoi200454r12","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study.","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi200454r13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial.","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi200454r14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi200454r15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10191","key":"zoi200454r16","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"issue":"10191","key":"zoi200454r17","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"zoi200454r18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-018-4967-8","article-title":"Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.","volume":"173","author":"Niraula","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"zoi200454r19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctrv.2017.08.001","article-title":"Duration of adjuvant trastuzumab in HER2 positive breast cancer: overall and disease free survival results from meta-analyses of randomized controlled trials.","volume":"60","author":"Gyawali","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"zoi200454r20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ctrv.2019.02.003","article-title":"Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: a meta-analysis of randomized controlled trials.","volume":"75","author":"Chen","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"zoi200454r21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-018-5001-x","article-title":"One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.","volume":"173","author":"Inno","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"zoi200454r22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan-Meier curves.","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"key":"zoi200454r24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"zoi200454r25","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"zoi200454r26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3, rating the quality of evidence.","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"zoi200454r27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1365-2125.2001.01397-3.x","article-title":"Points to consider on switching between superiority and non-inferiority.","volume":"52","author":"Committee for Proprietary Medicinal Products","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"zoi200454r23","unstructured":"Web Plot Digitalizer. Accessed July 27, 2020. https:\/\/automeris.io\/WebPlotDigitizer\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2769686\/gulia_2020_oi_200454_1602624522.89839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T22:01:23Z","timestamp":1602626483000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2769686"}},"subtitle":["An Individual Participant Data and Trial-Level Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.11777","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]}}}